These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 15531890)

  • 1. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
    Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylation inactivates the transcriptional repressor BCL6.
    Bereshchenko OR; Gu W; Dalla-Favera R
    Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
    Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
    Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
    Huynh KD; Bardwell VJ
    Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
    Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
    Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.
    Deltour S; Guerardel C; Leprince D
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14831-6. PubMed ID: 10611298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
    Phan RT; Dalla-Favera R
    Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.
    Baron BW; Anastasi J; Thirman MJ; Furukawa Y; Fears S; Kim DC; Simone F; Birkenbach M; Montag A; Sadhu A; Zeleznik-Le N; McKeithan TW
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2860-5. PubMed ID: 11854457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
    Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
    J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
    Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
    Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.
    Hatzi K; Jiang Y; Huang C; Garrett-Bakelman F; Gearhart MD; Giannopoulou EG; Zumbo P; Kirouac K; Bhaskara S; Polo JM; Kormaksson M; MacKerell AD; Xue F; Mason CE; Hiebert SW; Prive GG; Cerchietti L; Bardwell VJ; Elemento O; Melnick A
    Cell Rep; 2013 Aug; 4(3):578-88. PubMed ID: 23911289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
    Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
    Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
    Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
    Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation.
    Jaye DL; Iqbal J; Fujita N; Geigerman CM; Li S; Karanam S; Fu K; Weisenburger DD; Chan WC; Moreno CS; Wade PA
    J Pathol; 2007 Sep; 213(1):106-15. PubMed ID: 17573669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
    Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
    PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
    Ueda C; Akasaka T; Kurata M; Maesako Y; Nishikori M; Ichinohasama R; Imada K; Uchiyama T; Ohno H
    Oncogene; 2002 Jan; 21(3):368-76. PubMed ID: 11821949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
    Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
    Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.